P-536
P-536 is a ACE inhibitor that also inhibits herpes simplex virus HSV-1 thymidine kinase and Trypanosoma cruzi RNA polymerase. By inhibiting the renin-angiotensin system, downregulating the expression of AT1R and NOX4, and reducing oxidative stress (decreasing plasma hydrogen peroxide (H2O2) and 8-isoprostaglandin levels), P-536 effectively reduces systolic blood pressure and improves vascular reactivity. P-536 also inhibits the replication of DNA/RNA viruses such as HSV-1 by blocking nucleotide metabolism and nucleic acid synthesis, competitively inhibits RNA synthesis in Trypanosoma cruzi, and inhibits amastigote replication, thereby impeding its growth. P-536 is suitable for research on hypertension, insulin resistance, and Chagas disease.
For research use only. We do not sell to patients.
- CAS No.: 93426-60-9
- Formula: C44H39N3O19S
- Molecular Weight:945.86
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
|
RNA Polymerase |
Trypanosoma |
HSV-1 |
In Vitro
P-536 exhibits broad-spectrum antiviral activity. In their respective host cells, the CPE50 against adenovirus type 5 is 20 μg/mL, the CPE50 against HSV-1, poliovirus type 1 and encephalomyocarditis virus is 30 μg/mL, the CPE50 against vaccinia virus is 70 μg/mL, and the CPE50 against vesicular stomatitis virus, influenza A virus and measles virus is 100 μg/mL[3].
P-536 (10-200 μg/mL; 48 h) potently inhibits the production of HSV-1 infectious units in HeLa cells, with 10 μg/mL inducing 1-log inhibition and 50 μg/mL inducing 3-log inhibition, and no cytotoxicity is observed at these concentrations[3].
P-536 (100 μg/mL) blocks viral protein synthesis in HSV-1-infected HeLa cells when added at the onset of infection, but exerts no such effect when added 5 h post-infection[3].
P-536 (50-200 μg/mL; 2 h) inhibits the glycosylation of viral proteins in HSV-1-infected HeLa cells. Its inhibitory effect on mannose and galactose incorporation is stronger than that on glucosamine, and the inhibitory effect is observed at all tested concentrations[3].
P-536 (10-100 μg/mL; 8 h pre-treatment for RNA samples, 16 h pre-treatment for DNA samples) completely blocks the synthesis of HSV-1 TK mRNA in infected HeLa cells, and significantly reduces the accumulation of HSV-1 DNA at the concentration of 100 μg/mL[3].
P-536 (100 μg/mL; 5 min; co-incubated with [3H]thymidine) blocks thymidine phosphorylation in HSV-1-infected HeLa cells, and dTMP is barely detectable in the cellular nucleotide pool[3].
P-536 (150-200 μg/mL; 48 h (protein synthesis assay), 6 days (cell proliferation assay)) exhibits only extremely low cytotoxicity in mock-infected HeLa cells: the protein synthesis level at 200 μg/mL is consistent with that of the control group, and the inhibitory effect on cell proliferation at 150 μg/mL is less than 0.5-log[3].
P-536 (5-10 μg/mL; 8-10 d) potently inhibits the growth of extracellular Trypanosoma cruzi epimastigotes in vitro, with an ID50 of less than 5 μg/mL on the 8th day of culture[4].
P-536 (25 μg/mL; 3 d) inhibits the growth of Trypanosoma cruzi amastigotes in J774G8 cells, with an ID50 of 25 μg/mL on day 3 of culture[4].
P-536 (50 μg/mL; 4 d) restores J774G8 cells infected with Trypanosoma cruzi: administration at the onset of infection prevents parasite-induced cell death and restores normal cell growth, while administration at 12 hours post-infection reduces the infection load[4].
P-536 (10-100 μg/mL; 1 h) inhibits macromolecule synthesis in Trypanosoma cruzi epimastigotes; the inhibitory effect on RNA synthesis is the strongest at 100 μg/mL, but it does not induce significant plasma membrane leakage in Trypanosoma cruzi epimastigotes (only causes 17% of 86Rb+ efflux)[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Mock-infected HeLa cells
-
Concentration:150 μg/mL; 200 μg/mL
-
Incubation Time:6 days (cell proliferation); 48 h (protein synthesis)
-
Result:Did not reduce protein synthesis to below control levels at 200 μg/mL after 48 h.
Inhibited cellular proliferation by less than one-half log10 at 150 μg/mL after 6 days.
Chemical Information
-
CAS No. 93426-60-9
-
Molecular Weight 945.86
-
Formula C44H39N3O19S
-
SMILES
O(C(=O)C1=CC=CC=C1)[C@@H]2[C@@H](OC(=O)C3=CC=CC=C3)[C@@H](OC(NS(OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)N5C(=O)NC(=O)C=C5)(=O)=O)=O)O[C@H](COC(=O)C6=CC=CC=C6)[C@H]2OC(=O)C7=CC=CC=C7
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
References
[3]. Alarcón B, et al. Mode of action of a new type of UDP-glucose analog against herpesvirus replication. Antimicrob Agents Chemother. 1988;32(8):1257-1261. [Content Brief]
[4]. Alcina A, et al. Activity of P536, a UDP-glucose analog, against Trypanosoma cruzi. Antimicrob Agents Chemother. 1988;32(9):1412-1415. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- P-536
- 93426-60-9
- P536
- P 536
- Parasite
- Angiotensin-converting Enzyme (ACE)
- HSV
- DNA/RNA Synthesis
- NOX4
- Trypanosoma cruzi
- renin-angiotensin system
- epimastigotes
- angiotensin type 1 receptor
- HeLa cells
- J774G8 cells
- Trypanosoma cruzi RNA polymerase
- angiotensin converting enzyme
- herpes simplex virus type 1 thymidine kinase
- Inhibitor
- inhibitor
- inhibit